Sex Can Cause Genetic Changes In Women

Editor's Choice Main Category: Genetics Also Included In: Biology / Biochemistry Article Date: 12 Sep 2012 - 11:00 PDT

Current ratings for: Sex Can Cause Genetic Changes In Women

5 (1 votes)

A team of researchers from the University of East Anglia set out to determine the response female fruit flies (Drosophila melanogaster) have to mating.

The findings, published in Proceedings of the Royal Society B, indicated that semen consists of a single protein which generates a variety of responses in numerous genes in females, which appears evident at different instances and in different areas of their bodies after mating.

The discovery in the flies, the authors suggest, may be similar to responses in many animals, where semen is inserted into the female's body while having sex.

According to research earlier this year in PLoS Biology, neurodegenerative disorders that occur in both fruit flies and humans are caused by mutations in the same gene, showing that it is plausible that humans may experience the same effect during sex that fruit flies do with the activation of genes.

Scientists have been aware that males pass on seminal fluid proteins to their partner while mating, impacting their feeding, sleep patterns, immunity, egg laying, sexual receptivity, and water balance.

Professor Tracey Chapman, from UEA's school of Biological Sciences and head author, said:

Researchers identified significant changes to genes linked to:

Go here to see the original:
Sex Can Cause Genetic Changes In Women

Novel non-antibiotic agents against MRSA and common strep infections

Public release date: 12-Sep-2012 [ | E-mail | Share ]

Contact: Jessica Studeny jessica.studeny@case.edu 216-368-4692 Case Western Reserve University

Menachem Shoham, PhD, associate professor of biochemistry at Case Western Reserve University School of Medicine, has discovered novel antivirulence drugs that, without killing the bacteria, render Methicillin Resistant Staphylococcus Aureus (MRSA) and Streptococcus pyogenes, commonly referred to as strep, harmless by preventing the production of toxins that cause disease. The promising discovery was presented this week at the Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco.

MRSA infections are a growing public health concern, causing 20,000 to 40,000 deaths per year in the United States alone. It is the most prevalent bacterial pathogen in hospital settings and in the community at large, with about one million documented infections per year nationally, costing an estimated $8 billion annually to treat.

The problem has become increasingly severe as the bacteria have developed a resistance to antibiotics. As result, health care providers are running out of options to treat patients suffering from antibiotic-resistant infections, like MRSA and strep, creating a dire need for alternative treatments and approaches.

"Staph bacteria are ubiquitous and normally do not cause infections, however, occasionally these bacteria become harmful due to their secretion of toxins," says Dr. Shoham. "We have discovered potential antivirulence drugs that block the production of toxins, thus rendering the bacteria harmless. Contrary to antibiotics, these new antivirulence drugs do not kill the bacteria. Since the survival of the bacteria is not threatened by this approach, the development of resistance, like that to antibiotics, is not anticipated to be a serious problem."

Dr. Shoham identified a bacterial protein, known as AgrA, as the key molecule responsible for turning on the release of toxins. AgrA, however, needs to be activated to induce toxin production. His goal was to block the activation of AgrA with a drug, thus preventing the cascade of toxin release into the blood that can lead to serious infections throughout the body.

The screening for AgrA inhibitors was initially carried out in a computer by docking libraries of many thousands of "drug-like" compounds and finding out which compounds would fit best into the activation site on AgrA. Subsequently, about 100 of the best scoring compounds were tested in the laboratory for inhibition of the production of a toxin that ruptures red blood cells. Seven of these compounds were found to be active. Testing compounds bearing chemical similarity to the original compounds lead to the discovery of additional and more potent so-called "lead" compounds.

Optimization of the initial "lead" compounds was performed by chemical synthesis of 250 new compounds bearing small but important chemical modifications on one of the initial leads. More than a dozen active compounds have been discovered by this method. The best drug candidate reduces red blood cell rupture by 95 percent without affecting bacterial growth.

Beginning this fall, Dr. Shoham and colleagues will begin testing the drug candidate in animal models.

View post:
Novel non-antibiotic agents against MRSA and common strep infections

BYU breakthrough targets birth defects – BYU biochemistry professor Emily Bates has made recent discoveries that may …

BYU biochemistry professor Emily Bates has made recent discoveries that may revolutionize medicine

BYU research has shed light on the cause and prevention of birth defects as well as cancer.

BYU biochemistry professor Emily Bates and a few of her students recently preformed and published research that may lead to a permanent answer for birth defects and impact how cancer is treated.

Fetal Alcohol Syndrome anda rare condition called Andersen-Tawil Syndrome both cause birth defects like cleft palates, small or missing teeth andmisshapedor connected fingers and toes. Andersen-Tawil Syndrome is caused by genetic changes in a potassium channel, which is also the same channel blocked by consumption of alcohol.

Bates and her students made the revolutionary discovery that potassium channels help cells receive instructions that tell them what they are and where they should be.

Dr. Bates in the research lab

The instructions for cells to divide and move need to be sent during pregnancy while a baby is developing, but those signals should turn off after the baby is born so the cells stay where they are. In cancer cells, the signal has turned back on, allowing cells to metastasize or invade other tissues and allow for growth of new tumors.

Not only are Bates and her students excited to have found some information about the causes of Andersen-Tawil and Fetal Alcohol Syndrome, they are also excited to test a possible therapy to stop the spread of cancer cells throughout the body.

What happens later on in life if someone gets cancer, is that this pathway turns on when its not supposed to turn on anymore, Bates said. The cancer cells start to metastasize, or invade another tissue causing more tumors. What we hope is that blocking this channel will block a signaling pathway that drives metastasis.

In other words, if Bates and her students can eventually find a way to block the channel after it opens back up, cancer cells will not spread throughout the body once the original tumor is removed.

See the rest here:
BYU breakthrough targets birth defects - BYU biochemistry professor Emily Bates has made recent discoveries that may ...

Birth-defect mechanism found by BYU biochemists

Public release date: 11-Sep-2012 [ | E-mail | Share ]

Contact: Joe Hadfield joe_hadfield@byu.edu 801-422-9206 Brigham Young University

The cellular cause of birth defects like cleft palates, missing teeth and problems with fingers and toes has been a tricky puzzle for scientists.

Now Professor Emily Bates and her biochemistry students at Brigham Young University have placed an important piece of the developmental puzzle. They studied an ion channel that regulates the electrical charge of a cell. In a new study published by the journal Development, they show that blocking this channel disrupts the work of a protein that is supposed to carry marching orders to the nucleus.

Without those instructions, cells don't become what they were supposed to become be that part of a palate, a tooth or a finger. Though there are various disorders that lead to birth defects, this newly discovered mechanism may be what some syndromes have in common.

Bates and her graduate student, Giri Dahal, now want to apply the findings toward the prevention of birth defects particularly those caused by fetal alcohol syndrome and fetal alcohol spectrum disorder.

"What we think might be the case is that this is the target for a few similar disorders," Bates said. "The big thing that we have right now is that this ion channel is required for protein signaling, which means that developmental signaling pathways can sense the charge of a cell. And that's exciting for a lot of different reasons."

For example, the new study might also have implications for the battle against cancer. With cancer, the problem is that cells are receiving a bad set of instructions that tells them to multiply and spread. If they can devise a way to block the ion channel, it may stop those cancerous instructions from getting through.

"This protein signaling pathway is the same one that tells cancer cells to metastasize," Bates said. "We're planning to test a therapy to specifically block this channel in just the cells that we want to stop."

Bates, who received her Ph.D. in genetics from Harvard, authored the study with several BYU students. The experience has already helped launch two students into prestigious graduate programs: Brandon Gassaway is at Yale for a Ph.D. in molecular biology and Ben Kwok is at Ohio State University for dental school.

Original post:
Birth-defect mechanism found by BYU biochemists

‘Mad Cow’ blood test now on the horizon

Public release date: 11-Sep-2012 [ | E-mail | Share ]

Contact: Associate Professor Andrew Hill a.hill@unimelb.edu.au 61-425-784-778 University of Melbourne

Using newly available genetic sequencing scientists discovered cells infected with prions (the infectious agent responsible for these diseases) release particles which contain easily recognized 'signature genes'.

Associate Professor Andrew Hill from the Department of Biochemistry and Molecular Biology at the Bio21 Institute said these particles travel in the blood stream, making a diagnostic blood test a possibility.

"This might provide a way to screen people who have spent time in the UK, who currently face restrictions on their ability to donate blood," he said.

"With a simple blood test nurses could deem a prospective donor's blood as healthy, with the potential to significantly boost critical blood stocks."

Mad Cow disease was linked to the deaths of nearly 200 people in Great Britain who consumed meat from infected animals in the late 1980s.

Since 2000, the Australia Red Cross Blood Service has not accepted blood from anybody who lived in the UK for more than six months between 1980 and 1996, or who received a blood transfusion in the UK after 1980.

The research is published in this week's Oxford University Press Nucleic Acids Research journal http://nar.oxfordjournals.org/content/early/2012/09/08/nar.gks832.full.

Lead author Dr Shayne Bellingham said the breakthrough might also help detect other human neurodegenerative diseases, such as Alzheimer's and Parkinson's.

Read more from the original source:
'Mad Cow' blood test now on the horizon

PASSINGS: Robert Morgan Fink, Gene Vollnogle, Dorothy McGuire Williamson

Robert Morgan Fink

Biochemist at UCLA

Robert Morgan Fink, 96, a retired UCLA biochemistry professor whose groundbreaking research with his biochemist wife included developing a new technique in the late 1940s to study the thyroid, died Wednesday of natural causes at his Pacific Palisades home, said Suzanne Coppenrath, one of his two daughters.

He was a pioneer who "is remembered as a very good scientist who did important work," said Elizabeth Neufeld, former chairwoman of the department of biological chemistry at the David Geffen School of Medicine at UCLA.

At the University of Rochester, Fink met his future wife, Kathryn, a fellow graduate student. After marrying in 1941, they worked together at Rochester on the Manhattan Project, which would produce the atom bomb.

The head of the project at Rochester was Dr. Stafford Warren, who recruited the Finks to join the UCLA faculty after he was named the first dean of its school of medicine. When the couple came to UCLA in 1947, space for experiments was limited and at first they conducted research at hospitals in the San Fernando Valley and Long Beach.

The Finks were perhaps best known for a 1948 breakthrough in thyroid biochemistry called the "paper chromatography technique." They used radioactive "tracer" chemicals on small samples of the thyroid and other body tissues, which caused them to essentially photograph themselves and expose new and previously inconceivable detail.

The technique worked so well that the Finks were able to isolate and identify a dozen new biological compounds. The approach was later adapted to determine if chemotherapy was helping cancer patients.

In 1978, Robert Fink retired from UCLA as a biochemistry professor. His wife was assistant dean for student affairs at UCLA's medical school when she died at 72 in 1989.

Born Sept. 22, 1915, in Greenville, Ill., he was one of six children of a glove salesman who eventually owned the factory.

Go here to see the original:
PASSINGS: Robert Morgan Fink, Gene Vollnogle, Dorothy McGuire Williamson

Acceleron Founder Dr. Tom Maniatis To Receive The 2012 Lasker Award in Medical Science

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, announced that Tom Maniatis, Ph.D., an Acceleron co-founder and Professor and Chair of the Department of Biochemistry and Molecular Biophysics at the Columbia University College of Physicians and Surgeons, is to be honored with the 2012 Lasker-Koshland Special Achievement Award in Medical Science. The Albert and Mary Lasker foundation award is considered to be one of the most prestigious scientific prizes and the Special Achievement Award recognizes its recipients for exceptional leadership and citizenship in biomedical science. Dr. Maniatis will be presented with the Lasker-Koshland Special Achievement Award in Medical Science on September 21st in New York City.

Dr. Maniatis is a pioneer in the development of gene cloning technology, and he has published extensively in the field of eukaryotic gene regulation. In particular, he identified numerous genetic defects that underlie the inherited human illness -thalassemia. Dr. Maniatis is widely known for his seminal work developing gene cloning technologies and applying those methods to discovering the genetic bases of human diseases. His book, The Cloning Manual, has become a world-wide resource.

In addition to these scientific accomplishments, Dr. Maniatis has been instrumental in creating successful biotechnology companies. He was a co-founder of Genetics Institute, where he chaired the scientific board and served on the board of directors for more than 17 years. During this time, Genetic Institutes gained FDA approval for several protein-based drugs, including recombinant human erythropoietin, Factor VIII and Factor IX, as well as bone morphogenic proteins. Dr. Maniatis was also a co-founder of ProScript Inc., which discovered the drug Velcade (bortezomib). Dr. Maniatis is currently a member of the board of directors at Acceleron.

Mark Ptashne, Ph.D., the Ludwig Chair of Molecular Biology at Memorial Sloan-Kettering Cancer Center in New York, a co-founder of Genetics Institute and Acceleron, and a previous Lasker awardee said, Ive worked with Tom for many years in both basic science and biotechnology,he is simply the best.

Tom has had an enormous impact on the scientific community and an equally impressive contribution to the discovery and development of innovative medicines at several biotechnology companies, said John Knopf, Ph.D., Chief Executive Officer of Acceleron. I have had the distinct pleasure of knowing and working with Tom since I joined Genetics Institute 30 years ago. I personally continue to benefit significantly from his involvement at Acceleron as does our entire team of world-class scientists.

About Acceleron

Acceleron is a privately-held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel protein therapeutics for orphan diseases and cancer. Accelerons scientific approach takes advantage of its unique insight to discover first-in-class therapies based on the TGF- protein superfamily. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the companys internal GMP manufacturing capability to advance its therapeutic programs rapidly and efficiently. The investors in Acceleron include Advanced Technology Ventures, Alkermes, Avalon Ventures, Bessemer Ventures, Celgene, Flagship Ventures, MPM BioEquities, OrbiMed Advisors, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock. For further information on Acceleron, please visit http://www.acceleronpharma.com.

Continue reading here:
Acceleron Founder Dr. Tom Maniatis To Receive The 2012 Lasker Award in Medical Science

Proteonomix Retains Numoda Corporation to Provide Clinical Trial Services for Phase 1 Trial with UMK-121 in End-Stage …

PARAMUS, N.J.--(BUSINESS WIRE)--

Proteonomix, Inc. (PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced that Numoda Corporation will provide a range of specific clinical trial services for a Proteonomix-sponsored Phase 1 clinical trial with its patent-pending mobilization technology UMK-121 in patients with end-stage liver disease (ESLD). Numoda is leading provider of clinical trial information and logistics services to life sciences companies.

Initiating this clinical trial represents a major milestone for Proteonomix and we are delighted to report additional progress toward this goal, said Proteonomix Chief Technology Officer Steven Byle. UMK-121 combines two existing FDA-approved drugs with the intention of mobilizing mesenchymal stem cells from bone marrow to the peripheral circulation. This proprietary drug combination is designed to reduce inflammation and increase angiogenesis to restore liver function, potentially extending the life of ESLD patients awaiting liver transplant. We hope to begin this trial in the upcoming months.

Earlier this month, Proteonomix signed a master agreement with Numoda for clinical trial services. In August, the U.S. Food and Drug Administration granted Proteonomix permission to conduct a Phase 1 clinical trial with UMK-121 in patients with ESLD.

About Proteonomix, Inc.

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix family of companies includes Proteoderm, StromaCel, PRTMI and THOR Biopharma. Proteoderm is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel develops therapeutic modalities for the treatment of cardiovascular disease and plans to file an IND application for treatment of patients who have suffered post-myocardial infarction. Proteonomix Regenerative Translational Medicine Institute, Inc. (PRTMI) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Additional information is available at http://www.proteonomix.com and http://www.proteoderm.com.

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.

Read more:
Proteonomix Retains Numoda Corporation to Provide Clinical Trial Services for Phase 1 Trial with UMK-121 in End-Stage ...

Orchid Aesthetics Medical Spa is Launching an Aesthetic and Anti-Aging Center to Open in Midtown Manhattan at 57 West …

NEW YORK--(BUSINESS WIRE)--

Dr. Roxana Kerns the owner of Orchid Aesthetics Medical Spa, a board certified anesthesiologist and licensed aesthetic physician, is also embarking on the scientifically proven path of anti-aging medicine. By practicing Anti-aging medicine in conjunction with Aesthetics, Dr. Kerns will not only address the wrinkles or sagging of the face but also the bodys functional regeneration like cognition or autoimmune diseases. From skin care to cellular regeneration a complete anti-aging package at Orchid Aesthetics Medical Spa. Dr. Kerns is a certified physician in the science of telomerase (Dr. Elizabeth Blackburn was Awarded Nobel Prize in 2009) and an EXPERT Botox injector : From Botox to Nobel Prize depth, rest assured under the care of Dr. Roxana Kerns.

Orchid Aesthetics Medical Spa is launching an Anti-aging center to open in Midtown Manhattan at 57 WEST 57 STREET in October 2012. The Center will feature aesthetic and cosmetic non-surgical face and body treatments under highly specialized anti-aging and regenerative medicine scrutiny. By practicing Anti-aging medicine in conjunction with Aesthetics, Dr. Kerns will address not only the vitality of the skin but also the functional regeneration of body cells eg. cognition or autoimmune diseases.

Since Dr. Elizabeth Blackburn earned the NOBEL PRIZE IN MEDICINE for identifying telomerase, an enzyme that keeps our telomeres from shortening, a new natural remedy that contains activated telomerase was developed by TA-Sciences. Dr. Roxana Kerns of Orchid Aesthetics Medical Spa is a certified physician in the science of telomerase and a distributor for TA-65MD, a natural supplement (derived from astragalus root). Shortening of telomeres is associated with aging, disease states and death. Therefore TA-65MD, a concentrate of telomerase, by maintaining the telomeres (end divisions of our chromosomes) from getting too short, will prevent aging at structural and functional level.

At the opposite end, but extremely important for the busy New Yorker, Orchid Aesthetics, earlier this year, launched Dr. Kerns skin care line, which features medical strength natural products, tested and formulated in highly specialized pharmacies. Dr Kerns skin care was recently appreciated by customers as top of the line, since better skin means better health; it is based on botanical nutriceuticals, peptides and powerful anti-oxidants.

Dr. Roxana Kerns of Orchid Aesthetics Medical spa is committed to alleviate the aging pains of her clientele form the inside out. By combining science with innovative work Orchid Aesthetics Medical Spa and Anti-aging center is a nest for the ever-young New Yorker. Not only you can get a quick shot of Botox, as most walk- in clinics provide, BUT you can choose to have a complete anti-aging evaluation and treatment plan. Orchid Aesthetics Spa provides a soothing environment under the drapes of science.

57 west 57 street, the Mecca of Manhattan, easy accessible by foot, subway or bus is inviting you on! Experience a new YOU in the hands of Dr. Roxana Kerns, a true artist, as quoted by a patient in a recent testimonial. The difference between regular walk-in Botox Medi Spas and Orchid Aesthetics rests in the depth of evaluation and anti-aging treatment.

Testimonials and audio/video: http://www.orchidaesthetics.com/medspa-videos.html

About Orchid Aesthetics Medical Spa: opened in June 2008, features aesthetic and non-surgical cosmetic treatments like Botox/Dysport, Restylane, Fat Transfer and PRP, Laser skintight and hair removal, Sclerotherapy, Microdermabrasion, Chemical peels.

To learn more visit http://www.orchidaesthetics.com, http://ta-sciences.com/kerns/ta-65.html, http://www.nobelprize.org/nobel_prizes/medicine/laureates/2009/press.html.

See the article here:
Orchid Aesthetics Medical Spa is Launching an Aesthetic and Anti-Aging Center to Open in Midtown Manhattan at 57 West ...

Digital Solutions Inc Released the English Version of DS ANATOMY H&N Musculoskeletal Anatomical App

HIROSHIMA, Japan--(BUSINESS WIRE)--

Digital Solutions Inc. announces the release of English version of DS ANATOMY Head & Neck musculoskeletal anatomical application for iPad. The original application was released in May, 2012 for the Japanese market, and there were huge requests for the English version of this product from the global market since then. The English version is now downloadable from the Apple App Store from Sep. 12, 2012.

This app is very user friendly and it is sure that a user can be impressed with the reality of 3D models. A user can view the musculoskeletal systems in detail by zooming, hiding and rotating the realistic 3D models. And each musculoskeletal system has not only the explanation of features and action, but also the detailed pictures which help understanding. This app provides two contents of < Head and Neck Musculoskeletal system Anatomical model > and < Basic Knowledge of Myology > . Medical care beginner also can understand the basic knowledge of Myology.

View the single system at any angle even if it is overlapped. (Medical illustrations on the text cannot be viewed) Model the CG obtained from the CT scanned data of the real skull. Develop the accurate 3D models of bone, muscle, ligament, joint, membrane, salivary gland, endocrine, amygdala in detail by observing the actual donor body at the university. URL:http://ds-anatomy.com/eng/

This app can display the full model of head and neck anatomical structures and the muscles. A user can view the model at any angle as he likes. The all structures are displayed in full color. A user can switch the model in full view and in a single structure view, thus easily understand the accurate positional relationship of the structure.

Read more here:
Digital Solutions Inc Released the English Version of DS ANATOMY H&N Musculoskeletal Anatomical App

‘Bubble babies’ immune systems restored

LOS ANGELES UCLA stem cell researchers have found that a gene therapy regimen can safely restore immune systems to children with so-called "bubble boy" disease, a life-threatening condition that if left untreated can be fatal within one to two years.

In the 11-year study, researchers were able to test two therapy regimens for 10 children with ADA-deficient severe combined immunodeficiency (SCID), which has come to be known as "bubble boy" disease because some of its victims have been forced to live in sterile environments.

During that time, the researchers refined their approach to include a light dose of chemotherapy to help remove many of the blood stem cells in the bone marrow that were not creating the enzyme adenosine deaminase (ADA), which is critical for the production and survival of healthy white blood cells, said study senior Dr. Donald Kohn, a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA.

The refined gene therapy and chemotherapy regimen proved superior to the other method tested in the study, restoring immune function to three of the six children who received it, said Kohn, who is also a professor of pediatrics and of microbiology, immunology and molecular genetics in UCLA Life Sciences Division. An even further-refined regimen using a different type of virus delivery system will be studied in the next phase of the study, which already has enrolled eight of the 10 patients needed.

The study appears today (Sept. 11) in the advance online issue of the peer-reviewed journal Blood.

"We were very happy that in the human trials we were able to see a benefit in the patients after we modified the protocol," Kohn said. "Doctors treating ADA-deficient SCID have had too few options for too long, and we hope this will provide them with an efficient and effective treatment for this devastating disease."

Children born with SCID, an inherited immunodeficiency, are generally diagnosed at about 6 months old. They are extremely vulnerable to infectious diseases and don't grow well. Chronic diarrhea, ear infections, recurrent pneumonia and profuse oral candidiasis commonly occur in these children. SCID occurs in about one of every 100,000 births.

Currently, the only treatment for ADA-deficient SCID calls for injecting patients twice a week with the necessary enzyme, Kohn said, a lifelong process that is very expensive and often doesn't return the immune system to optimal levels. These patients also can undergo bone marrow transplants from matched siblings, but matches can be very rare.

About 15 percent of all SCID patients are ADA-deficient. Kohn and his team used a virus delivery system that he had developed in his lab in the 1990s to restore the gene that produces the missing enzyme necessary for a healthy immune system. To date, about 40 children with SCID have received gene therapy in clinical trials around the world, Kohn said.

Two slightly different viral vectors were tested in the study, each modified to deliver healthy ADA genes into the bone marrow cells of the patients so the needed enzyme could be produced and make up for the cells that don't have the gene. Four of the 10 patients in the study remained on their enzyme replacement therapy during the gene therapy study. There were no side effects, but their immune systems were not sufficiently restored, Kohn said.

The rest is here:
'Bubble babies' immune systems restored

UCLA stem cell researchers use gene therapy to restore immune systems in ‘bubble babies’

Public release date: 11-Sep-2012 [ | E-mail | Share ]

Contact: Kim Irwin kirwin@mednet.ucla.edu 310-435-9457 University of California - Los Angeles Health Sciences

UCLA stem cell researchers have found that a gene therapy regimen can safely restore immune systems to children with so-called "Bubble Boy" disease, a life threatening condition that if left untreated can be fatal within one to two years.

In the 11-year study, researchers were able to test two therapy regimens for 10 children with ADA-deficient severe combined immunodeficiency (SCID). During the study, they refined their approach to include a light dose of chemotherapy to help remove many of the blood stem cells in the bone marrow that are not creating an enzyme called adenosine deaminase (ADA), which is critical for the production and survival of healthy white blood cells, said study senior Dr. Donald Kohn, a professor of pediatrics and of microbiology, immunology, and molecular genetics in Life Sciences and a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA.

The refined gene therapy and chemotherapy regimen proved superior to the other method tested in the study, restoring immune function to three of the six children who received it, Kohn said. Going forward, an even further refined regimen using a different type of virus delivery system will be studied in the next phase of the study, which already has enrolled eight of the 10 patients needed.

The study appears Aug. 30 in the advance online issue of the peer-reviewed journal Blood.

"We were very happy that in the human trials we were able to see a benefit in the patients after we modified the protocol," Kohn said. "Doctors treating ADA-deficient SCID have had too few options for too long, and we hope this will provide them with an efficient and effective treatment for this devastating disease."

Children born with SCID, an inherited immunodeficiency, are generally diagnosed at about six months. They are extremely vulnerable to infectious diseases and don't grow well. Chronic diarrhea, ear infections, recurrent pneumonia and profuse oral candidiasis commonly occur in these children. SCID cases occur in about 1 of 100,000 births

Currently, the only treatment for ADA-deficient SCID calls for injecting the patients twice a week with the necessary enzyme, Kohn said, a life-long process that is very expensive and often doesn't return the immune system to optimal levels. These patients also can undergo bone marrow transplants from matched siblings, but matches can be very rare.

About 15 percent of all SCID patients are ADA-deficient. Kohn and his team used a virus delivery system that he had developed in his lab in the 1990s to restore the gene that produces the missing enzyme necessary for a healthy immune system. To date, about 40 children with SCID have received gene therapy in clinical trials around the world, Kohn said.

Original post:
UCLA stem cell researchers use gene therapy to restore immune systems in 'bubble babies'

Enzymotec Presents Clinical Trials Strategy for Its Infant Nutrition Lipid Based Ingredients

KFAR BARUCH, Israel, September 11, 2012 /PRNewswire/ --

Enzymotec Ltd. reports today that clinical trials for its lipid-based ingredient line for infant nutrition yielded positive results. This plan is part of a comprehensive business development strategy to develop and market directly or through its affiliated companies a line of products mimicking the vital lipids found in mother's milk, such as triglyceride, phospholipids and long-chain polyunsaturated fatty acids (LCPUFA).

Enzymotec intends to publish four new scientific articles on its lipid-based ingredients for infant nutrition in peer-reviewed journals in the coming months. These large-scale clinical research trials were conducted on newborn term infants in several institutes worldwide. Clinical results already have been presented at leading professional conferences.

One of the studies recently completed was a controlled clinical trial on InFat. InFat is a beta-palmitate ingredient that successfully mimics the fat composition and properties of human milk fat. It enables easy digestion and optimized uptake of calcium, fat recovery and energy. InFat is marketed by Advanced Lipids, a joint venture of AAK and Enzymotec. The study was the first testing the positive effect of a commercial term-infant formula containing beta-palmitate on Chinese infants' well-being. It was conducted by Professor Chen Yu-Ming, the principle investigator at Sun Yat-Sen University and in collaboration with Enzymotec.

"The clinical trials plan represents Enzymotec's ongoing commitment to explore the special characteristics of human milk and demonstrate its lipid-based ingredients' health benefits on various infant populations," says Yael Lifshitz, PhD, Director of R&D, of Enzymotec Infant Nutrition. "We developed this innovative ingredient and educated the premium infant formula market over the last several years. Enzymotec invested 10% of its revenue in research and development-a percentage considered among the highest in the industry."

About Enzymotec

Enzymotec is a research-based biotech company that develops, manufactures and markets innovative lipid-based, bio-functional ingredients and final products. Enzymotec delivers innovative solutions under three divisions. The Enzymotec Infant Nutrition division develops lipid compositions that mimic human milk fat to facilitate healthy infant development.

About Advanced Lipids AB

Advanced Lipids is a joint venture between AAK and Enzymotec for the sales and marketing of InFat. Advanced Lipids offers InFat as a concentrate form or as any tailored oil blend enriched with beta-palmitate (high sn2). Advanced Lipids produces InFat at AAK's site in Karlshamn, Sweden, based on the enzymatic technology developed by Enzymotec.

The rest is here:
Enzymotec Presents Clinical Trials Strategy for Its Infant Nutrition Lipid Based Ingredients

Schiff Nutrition Announces Timing of Fiscal 2013 First Quarter Results

SALT LAKE CITY--(BUSINESS WIRE)--

Schiff Nutrition International, Inc., (SHF), announced it intends to discuss its fiscal 2013 first quarter results on Tuesday, September 18, 2012. The company will host a conference call at 11:00 a.m. ET, featuring remarks by Tarang Amin, chief executive officer and president, and Joseph Baty, chief financial officer and executive vice president, followed by a question and answer session.

The call will be webcast at http://www.schiffnutrition.com/press_conference_calls.asp. The webcast replay will be available for 90 days. If you do not have Internet access, the dial-in number will be 888-771-4371 for domestic callers and 847-585-4405 for international callers. The participant access code is 33249843. A replay of the call will be available by dialing 888-843-7419 for domestic callers and 630-652-3042 for international callers, and entering access code 33249843. The telephone replay will be available through September 25, 2012.

About Schiff Nutrition

Schiff Nutrition International, Inc. is a leading nutritional supplement company offering vitamins, nutritional supplements and nutrition bars in the United States and abroad. Schiffs portfolio of well-known brands includes MegaRed, Move Free, Airborne, Tiger's Milk, Digestive Advantage and Schiff Vitamins. Focused on quality for 75 years, Schiffs headquarters and award-winning manufacturing and distribution facility are based in Salt Lake City, Utah. To learn more about Schiff, please visit the web site http://www.schiffnutrition.com.

See more here:
Schiff Nutrition Announces Timing of Fiscal 2013 First Quarter Results

DNA leads to arrest in cemetery thefts

Man admits to theft at cemetery

Investigators were able to use DNA evidence to track down a man who has been accused of stealing thousands of dollars worth of equipment from the Houston National Cemetery.

According to investigators, a burglar got away with a golf cart, two John Deere utility carts, tools and damaged two trucks in December of last year. The cemetery's losses totaled $36,000.

Harris County sheriff's deputies said the burglar left behind a drop of blood. Using a national database, the blood was matched to 32-year-old David Torres, a convict with arrests for theft, burglary and drugs that date back to 1997.

Torres was forced to submit a DNA sample during his last stay in jail.

"At that point, when the CODIS was done, he was brought in, presented with the evidence and he couldn't fight it. He pled guilty with no jury," said Deputy Thomas Gilliam with the Harris County Sheriff's Department.

Torres is now serving three years in prison for looting the Houston National Cemetery.

The same DNA evidence also showed that Torres was a suspect in a second burglary.

Copyright 2012 by Click2Houston.com. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Follow this link:
DNA leads to arrest in cemetery thefts

Posted in DNA

Real-time observation of single DNA molecule repair

ScienceDaily (Sep. 11, 2012) DNA is constantly being damaged by environmental agents such as ultraviolet light or certain compounds present in cigarette smoke. Cells unceasingly implement repair mechanisms for this DNA, which are of redoubtable efficacy. A team from Institut Jacques Monod (CNRS/Universit Paris Diderot), in collaboration with scientists from the Universities of Bristol in the UK and Rockefeller in the USA, has for the first time managed to follow real-time the initial steps in one of these hitherto little known DNA repair systems. Working in a bacterial model, and thanks to an innovative technique applied to a single molecule of DNA, the scientists were able to understand how several actors interact to ensure the reliable repair of DNA.

Published in Nature on 9 September 2012, their work aims to better understand the onset of cancers and how they become resistant to chemotherapies.

Ultraviolet light, tobacco smoke or even the benzopyrenes contained in over-cooked meat can cause changes to the DNA in our cells, which may lead to the onset of cancers. These environmental agents deteriorate the actual structure of the DNA, notably causing so-called "bulky" lesions (like the formation of chemical bonds between DNA bases). In order to identify and repair this type of damage, the cell can call on several systems, such as transcription-coupled repair (TCR), whose complex mechanism of action still remains poorly understood today. Abnormalities affecting this TCR mechanism -- which permits permanent monitoring of the genome -- are the cause of some hereditary diseases such as Xeroderma pigmentosum, sufferers from which are hypersensitive to the Sun's ultraviolet rays and are commonly referred to as "children of the night."

For the first time, a team from Institut Jacques Monod (CNRS/Universit Paris Diderot), in collaboration with scientists at the Universities of Bristol in the UK and Rockefeller in the USA, has succeeded in observing the initial stages of TCR repair mechanisms in a bacterial model. To achieve this, they employed a novel technique for the nanomanipulation of individual molecules[1] which allowed them to detect and follow real-time the interactions between the molecules in play in a single damaged DNA molecule. They elucidated the interactions between different actors during the first steps of this TCR process. A first protein, RNA polymerase[2], usually crosses DNA without mishap, but is stalled when it meets a bulky lesion (like a train blocked on its rails by a landslide). A second protein, Mfd, binds to the stalled RNA polymerase and removes it from the damaged "rail" so that it can then replace it with the other proteins necessary to repair the damage. Measurements of the reaction speeds enabled the observation that Mfd acts particularly slowly on RNA polymerase, pushing it out of the way in about twenty seconds. Furthermore, Mfd does indeed displace stalled RNA polymerase, but then remains associated with the DNA for a longer period (of about five minutes), allowing it to coordinate the arrival of other repair proteins at the damaged site.

Although the scientists were able to explain how this system can achieve almost 100% reliability, a even clearer understanding of these repair processes is still essential in order to determine how cancers appear and subsequently may become resistant to chemotherapies.

Notes:

[1] During these nanomanipulation experiments, damaged DNA was grafted onto a glass surface on one side and a magnetic microbead on the other. The bead surface enabled the perpendicular extension of the DNA and measurement of this end-to-end extension using videomicroscopy. The binding to DNA of different proteins, and their action, is identifiable from the modification the protein generates in the structure or conformation of the DNA. This technique enables an extremely detailed structural and kinetic analysis of in vitro biochemical reactions.

[2] RNA polymerase is responsible for the reading of DNA by a gene and its rewriting in an RNA form, a process known as transcription. It has been shown that RNA polymerase does not only transcribe genes, but also the DNA between genes (until recently referred to as "junk" DNA), allowing, for example, polymerase RNA to perform its quality control by TCR on the entire genome of an organism.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Read the original post:
Real-time observation of single DNA molecule repair

Posted in DNA

Ex-professor pleads guilty to fatally shooting 3 colleagues at Ala. university faculty meeting

BIRMINGHAM, Ala. A former biology professor accused of pulling a gun from her purse and opening fire at a faculty meeting pleaded guilty Tuesday to killing three colleagues and wounding three others at the University of Alabama in Huntsville in 2010.

Amy Bishop, 47, pleaded guilty to one count of capital murder involving two or more people and three counts of attempted murder during a hearing in Huntsville. She had earlier pleaded not guilty, and her lawyers said she planned to use an insanity defense.

Prosecutors agreed to recommend a sentence of life without parole for the capital charge, and three life sentences for the attempted murder charges. Sentencing will follow a brief trial on Sept. 24 before Madison County Circuit Judge Alan Mann.

Prosecutors say Bishop opened fire at the meeting on Feb. 12, 2010. Her attorneys say Bishop had mental problems; she signed a plea agreement with a barely legible scrawl.

Bishop, who lived with her family in Huntsville before the shootings, also is charged with killing her brother in Massachusetts in 1986. The shooting of 18-year-old Seth Bishop had been ruled an accident after Amy Bishop told police she shot him in the family's Braintree home as she was trying to unload her father's gun.

But the Alabama slayings led to a new investigation and charges.

In the school shooting, police and people who knew Bishop have described the Harvard University-educated researcher as being angry over UAH's refusal to grant her tenure, a decision that effectively would have ended her employment in the biology department.

The gunfire killed Bishop's boss, biology department chairman Gopi Padila, plus professors Maria Ragland Davis and Adriel Johnson. Professors Joseph Leahy, staff aide Stephanie Monticciolo and assistant professor Luis Cruz-Vera were shot and wounded.

Debra Moriarity was in the faculty meeting at the time of the shooting and is now biology chairman at the school. Prosecutors who met with potential witnesses last Friday said there was a possibility of a plea agreement before the trial began on Sept. 24, she said.

"So I'm not totally surprised by it, but I am surprised it happened this soon," she said.

See the original post:
Ex-professor pleads guilty to fatally shooting 3 colleagues at Ala. university faculty meeting

The Contrarian: Set Scientists Free to Create New Life-Forms | DISCOVER Magazine

UT Austin 2004 Synthetic Biology competition photo.

Courtesy of Jeff Tabor and Randy Rettberg via Wikipedia

CONVENTIONAL WISDOMSynthetic biology could destabilize the environment and revive viral terrors like the killer flu of 1918.

THE CONTRARY VIEWSynthetic life is proven safe and should be unleashed.

Synthetic biology is based on identifying DNA sequences that code for specific traits and transferring them from one life-form to another, such as from fish to bacteria. The goal is to create new living things with specialties that help humans and the Earth. Sequences are catalogued, and innovators can then request one that confers special traits as simply as ordering a book online.

advertisement | article continues below

Off-the-shelf molecular parts could allow synthetic biologists to create new medications and biofuels or to make microbes with the capacity to destroy pollutants and other nuisances. Researchers have built a potential malaria medication, and students have developed a prototype of a new vaccine to stop ulcers.

Shamefully, accolades that resounded a generation ago for biotechnology advancesfor instance, recombining DNA to develop human-derived insulin, which is much safer than the animal-derived products that came beforehave been drowned out by a misinformed coalition of 114 organizations, including ETC Group and Friends of the Earth. They argue the research must stop until enforceable regulations specific to synthetic biology are in place, and they insist that all alternatives to synthetic biology be considered before an experiment can advance. These demands could halt projects like those of J. Craig Venter, the biotechnologist who built the first self-replicating synthetic bacterium. He is now working on microbes that eat pollution, excrete biofuels, and more. If the coalition has its way, the world will never find out whether these organisms can help us generate energy or clean the air.

There is no documented danger from synthetic biology, yet merchants of doom emphasize fears of molecular Frankenbots instead of benefits like new drugs and energy sources. Worries about monster species are particularly absurd. It is extraordinarily difficult to construct novel organisms, and countless attempts to do so have failed.

Brent Erickson, executive vice president of the Biotechnology Industry Organization, believes at the core of the opposition is a phobia of technology and genetically modified crops. They see synthetic biology as a gateway to biofuels and consider that a Trojan horse for genetically modified crops. Thats a very tangled fearmany of its products are good for humanity, he says.

Read more here:
The Contrarian: Set Scientists Free to Create New Life-Forms | DISCOVER Magazine

Johns Hopkins biology professor wins top research award

Donald Brown (Courtesy of Johns Hopkins, Baltimore Sun / September 11, 2012)

5:03 p.m. EDT, September 11, 2012

Brown, who also is director emeritus of the Carnegie Institution for Science Department of Embryology, was recognized for work he and others did in gene amplification, one process that is responsible for runaway growth of chemotherapy-resistant cancer cells. He has made other discoveries about the nature of genes but today focuses on metamorphosis in frogs.

"We were one of the first groups to purify genes of any kind," Brown said in a statement. "We learned a lot about their structure, function, and evolution before the era of recombinant DNA."

Another Hopkins affiliated biologist, Joseph Gall, won the Lasker Award in 2006 for his role as a "founder of modern cell biology." Four other Hopkins faculty have won the award for work including on brain chemistry and the discovery that vitamin A prevents blindness and infections in children in poor countries.

meredith.cohn@baltsun.com

Excerpt from:
Johns Hopkins biology professor wins top research award

Partnership enhances biology teaching at California community colleges

Public release date: 11-Sep-2012 [ | E-mail | Share ]

Contact: Elaine Bible ebible@sfsu.edu 415-405-3606 San Francisco State University

When student Jeff Schinske took part in a graduate teaching fellowship through Associate Professor of Biology Kimberly Tanner's lab at San Francisco State University, the experience inspired him to teach biology. But when he graduated and became a community college instructor, Schinske found there was little professional support.

Schinske and Tanner are collaborating on a project that meets that need. With funding from the National Science Foundation, they are bringing together Bay Area community college biology instructors and helping them find innovative ways to refine their teaching.

"It can be isolating to be a community college instructor," said Schinske, who teaches biology at De Anza College in Cupertino, Calif. "Unlike K-12 teachers or university professors, you don't have a professional community centered on the grade level you teach or your field of research."

A lack of professional community isn't the only challenge.

"Much like university faculty, community college biology instructors are trained to conduct scientific research but they aren't trained how to teach," Tanner said.

She runs a range of programs for current and aspiring science educators through SF State's Science Education Partnership and Assessment Lab (SEPAL).

"I teach science instructors to be the best teachers that they can be," Tanner said. "This community partnership is an extension of that work." Community College Biology Faculty Enhancement through Scientific Teaching (CCB FEST) began in in 2010 and just received another NSF grant to support it for the next four years. The program includes monthly workshops, a summer intensive session, discussion groups and opportunities for community college faculty to partner with SF State graduate students.

The program encourages community college instructors to apply the rigor of scientific research to their teaching, collecting evidence from students about what they are learning and using that to refine how they teach. The approach is called scientific teaching.

View post:
Partnership enhances biology teaching at California community colleges